Vinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumonia.
The aim of the present study was to investigate the efficacy and tolerability of vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or relapse) non-small cell lung cancer (NSCLC) with interstitial pneumonia (IP). A total of 67 patients treated with vinorelbine and cisplatin as a first-line chemo therapy between January 2002 and December 2013 were retrospectively reviewed. The overall response rate was 34.3% [95% confidence interval (CI)=22.9%-45.7%). The median progression-free survival, median overall survival, and 1-year survival rates were 3.7 months (95% CI=3.1-4.3 months), 7.4 months (95% CI=5.4-9.4 months), and 22.4% (95% CI=12.4%-32.4%), respectively. The incidence of acute exacerbation of IP following first-line chemotherapy was 10.4%. The combination of vinorelbine and cisplatin is a feasible treatment option for advanced NSCLC patients with IP, after careful consideration of the potential risks and benefits on an individual basis.